Gilead sciences, inc. (GILD)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09
Operating Activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

4,934

5,364

2,678

5,945

5,889

5,460

1,621

2,234

3,484

4,644

11,579

12,192

12,620

13,488

15,074

16,341

17,341

18,106

16,883

15,015

14,168

12,059

9,383

7,444

4,562

3,057

3,029

2,915

2,854

2,574

2,476

2,542

2,579

2,789

2,753

2,718

2,684

2,889

3,062

3,031

2,891

2,625

0

0

0

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense

263

255

243

234

230

226

247

242

240

233

203

195

184

177

174

171

166

161

147

147

138

125

120

105

103

103

98

93

87

83

79

76

73

72

71

69

68

67

69

69

68

64

0

0

0

Amortization expense

1,131

1,149

1,169

1,189

1,201

1,203

1,221

1,165

1,109

1,053

978

988

985

981

970

952

946

937

948

938

940

925

782

598

408

242

191

198

198

195

198

203

213

230

235

232

218

198

182

170

165

148

0

0

0

Stock-based compensation expense

634

636

654

690

768

845

1,004

919

769

638

406

388

381

380

375

377

378

382

380

383

370

360

336

299

272

252

237

229

222

209

198

189

191

192

199

204

202

200

188

185

186

180

0

0

0

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

622

594

511

482

468

403

395

279

217

167

131

114

75

55

49

40

43

41

46

81

89

107

109

80

0

0

0

Tax benefits from exercise and vesting of stock-based awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

623

594

512

484

475

411

404

285

221

171

133

113

72

50

43

37

38

37

42

82

92

112

116

88

0

0

0

Deferred income taxes

2,130

2,098

-1,095

-259

-300

-289

-35

-58

59

82

341

373

162

119

-144

17

287

393

611

443

354

236

152

160

140

98

72

50

51

39

-42

-46

-94

-64

-12

-82

-63

-12

-12

51

61

42

0

0

0

Net unrealized loss (gain) from equity securities

761

1,241

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Up-front and milestone expense related to collaborative and other arrangements

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development impairment

-

-

-

-

-

-

-

-

-

-

-

-

-

432

231

114

114

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-203

-184

-167

-107

-162

-171

-240

-245

-314

-304

-247

-233

-133

-162

-670

-653

-633

-562

118

103

107

101

99

102

110

105

-50

-28

2

-3

97

53

26

47

-37

-20

-5

-10

-1

27

27

64

0

0

0

Changes in operating assets and liabilities:
Accounts receivable, net

626

218

-146

-135

-411

-480

-648

-913

-318

-754

-895

-1,120

-1,920

-1,192

-983

397

1,240

1,397

3,361

2,056

1,808

2,578

915

1,465

1,201

315

189

163

-162

-198

-6

-26

464

375

218

328

292

348

418

380

431

356

0

0

0

Inventories

65

95

154

288

311

310

365

273

262

253

293

405

479

488

470

318

499

855

617

470

142

-143

25

163

370

343

341

337

380

350

288

299

130

200

69

-41

83

161

263

399

238

75

0

0

0

Prepaid expenses and other

218

307

71

-247

-331

-903

-796

-835

-710

-358

-576

40

217

520

708

298

268

90

109

-24

150

371

487

538

151

170

130

250

241

129

136

57

65

13

51

59

100

70

38

75

59

65

0

0

0

Accounts payable

31

-61

36

-12

-148

-39

-132

-224

-260

-430

-353

-285

24

47

-177

-461

-71

226

74

421

-211

-289

-196

-252

-148

-98

-6

-48

40

117

317

363

360

428

111

28

29

-4

210

422

366

203

0

0

0

Income taxes payable

394

272

199

105

-1,090

-1,459

3,994

3,587

4,903

5,497

-67

437

781

1,010

775

340

325

269

920

809

441

533

253

285

258

30

-79

76

43

-68

-50

-42

-19

110

34

30

-4

-185

-87

-48

-33

166

0

0

0

Accrued liabilities and other

-522

-389

-914

-1,321

-1,095

-514

-118

-150

23

-818

-1,791

-893

-732

305

1,797

2,146

2,172

3,342

3,374

3,181

3,377

2,013

1,349

956

310

312

137

272

373

317

583

470

341

292

129

187

162

120

126

156

117

109

0

0

0

Deferred revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

363

376

89

31

4

24

-7

22

44

29

35

23

10

26

-0

-29

-31

-64

-36

-29

41

56

64

48

0

0

0

Net cash provided by operating activities

9,003

9,144

8,909

8,222

7,707

8,400

8,808

9,290

11,243

11,898

12,684

14,383

15,842

17,047

19,303

19,006

19,679

21,250

18,476

18,424

16,951

12,818

10,523

7,232

4,000

3,105

3,084

3,076

3,414

3,195

3,467

3,618

3,271

3,639

3,385

3,228

2,983

2,833

3,064

3,185

3,109

3,080

0

0

0

Investing Activities:
Purchases of marketable debt securities

36,891

30,455

28,504

25,246

16,558

10,233

10,287

12,054

20,229

23,314

24,551

26,866

24,124

25,619

24,829

22,414

19,754

17,239

12,866

8,304

4,475

2,107

1,534

707

288

257

350

837

1,307

1,245

2,115

3,020

3,608

5,127

5,863

6,200

5,519

5,502

4,497

3,439

3,237

2,614

0

0

0

Proceeds from sales of marketable debt securities

16,604

7,523

4,843

2,410

1,876

1,522

2,675

3,487

7,488

10,440

11,629

14,085

13,253

13,039

12,704

10,232

7,502

4,792

2,794

1,711

973

807

744

573

511

494

623

624

537

528

5,281

6,487

7,420

8,649

4,724

3,657

4,045

3,033

2,062

2,049

1,126

1,440

0

0

0

Proceeds from maturities of marketable debt securities

19,336

22,398

24,954

22,826

26,085

24,336

20,678

17,418

11,849

7,821

4,733

2,858

1,991

1,700

1,479

1,355

1,124

719

396

182

76

52

47

56

85

78

76

81

51

45

307

442

619

788

598

726

681

683

664

502

479

435

0

0

0

Up-front and milestone payments related to collaborative and other arrangements

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of equity securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Acquisitions, net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

379

379

379

379

10,752

10,751

10,751

11,119

588

0

0

0

-

-

-

-

-

-

-

-

Purchases of other investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Capital expenditures

759

825

870

837

949

924

896

858

684

590

539

608

689

748

745

833

800

747

748

597

517

557

458

360

315

190

391

420

412

397

153

150

140

131

129

75

65

61

65

72

77

230

0

0

0

Other

202

384

380

390

352

190

8

102

20

0

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-7,917

-7,817

-5,513

-1,393

9,757

14,355

1,604

-2,535

-12,022

-16,069

-8,728

-10,531

-9,569

-11,985

-11,748

-12,017

-12,285

-12,475

-10,442

-7,026

-3,961

-1,823

-1,201

-439

-7

-254

-420

-930

-1,510

-11,846

-7,455

-7,018

-6,852

3,589

-1,258

-2,572

-1,169

-1,937

-1,927

-960

-2,956

-2,215

0

0

0

Financing Activities:
Proceeds from debt financing, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,932

3,965

3,966

3,968

0

-0

-0

-0

2,144

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from convertible note hedges

-

-

-

-

-

-

-

-

-

-

-

-

-

956

1,140

1,232

725

784

1,514

1,739

2,096

2,543

3,145

2,880

3,274

2,774

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of convertible note hedges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26

26

26

26

0

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuances of senior notes, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuances of common stock

283

209

232

271

281

289

290

274

249

234

211

207

212

208

218

237

293

319

337

370

340

331

347

329

335

313

356

410

419

466

403

297

285

211

212

192

176

221

228

264

285

222

0

0

0

Proceeds from credit facilities, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Repayments of Credit Facility

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Repurchases of common stock

2,243

1,749

2,606

2,833

2,695

2,900

2,044

1,748

1,428

954

1,848

2,695

3,566

11,001

13,052

15,102

15,001

10,002

8,952

7,600

7,900

5,349

3,747

2,149

949

582

382

487

728

667

693

1,372

1,855

2,383

2,772

3,441

4,408

4,022

3,649

2,384

930

998

0

0

0

Repayments of debt and other obligations

2,500

2,750

2,750

3,000

2,500

6,250

7,971

6,251

6,281

1,811

820

795

1,885

1,981

1,485

1,593

924

997

2,682

2,990

3,559

4,779

5,075

4,743

5,511

4,440

3,013

3,274

1,836

1,839

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of other long-term obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

0

1

1

1

7

5

5

11

5

5

0

0

0

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

622

594

511

482

468

403

395

279

217

167

131

114

75

55

49

40

43

41

46

81

89

107

109

80

0

0

0

Payments of dividends

3,279

3,222

3,157

3,095

3,035

2,971

2,917

2,857

2,797

2,731

2,668

2,609

2,555

2,455

2,450

2,454

2,461

1,874

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-140

-122

-127

-137

-140

-486

-653

-633

-686

-330

-168

-258

-247

-276

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Contributions from (distribution to) noncontrolling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

237

12

111

35

10

105

92

152

179

188

208

131

47

-66

-163

-115

-41

40

80

131

78

24

-42

-44

0

0

0

Net cash used in financing activities

-7,879

-7,634

-8,408

-8,794

-8,089

-12,318

-7,301

-2,230

-1,958

3,393

-2,302

-1,675

-2,356

-9,725

-11,842

-7,995

-11,775

-5,884

-185

-12,601

-8,631

-3,025

-5,104

-274

539

-2,544

-2,209

-1,574

-1,491

563

4,599

4,031

3,134

1,763

-2,222

-1,076

-869

-1,338

-1,203

-1,898

-889

-1,051

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-83

-2

-83

-29

-91

-85

-50

-3

95

137

45

50

53

41

131

74

61

-67

-93

-111

-128

-56

-20

9

7

2

5

5

-0

8

30

87

63

-16

-18

-156

-45

77

64

115

9

0

0

0

0

Net change in cash and cash equivalents

-6,876

-6,309

-5,095

-1,994

9,284

10,352

3,061

4,522

-2,642

-641

1,699

2,227

3,970

-4,622

-4,156

-932

-4,320

2,824

7,756

-1,314

4,231

7,914

4,197

6,528

4,539

309

460

576

412

-8,080

641

719

-384

8,975

-113

-576

899

-365

-1

441

-726

-186

0

0

0